Loading...

ADVM ADVERUM BIOTECHNOLOGIES INC Expansion Plans 8-K Filing

DVRM

DVM

ADVERUM BIOTECHNOLOGIES INC

(ADVM)

2024 8-K

Show Summary

Show Summary

Management Changes

Financial Statements

Financial Results

Financial Restatement

Positive Trial Results

Financial Results

Financial Results

Corporate Presentation and ...

Annual Meeting Results

Appointment and Resignation...

Financial Results Announcement

Reverse Stock Split

Financial Results Announcement

Corporate Presentation Upda...

Settlement Agreement for St...

Securities Purchase Agreement

Delisting Notice

Appointment of Dr. Nicholson

Financial Results Announcement

Appointment of Director

Earnings Reports

Appointment of CFO

Compliance regained with Na...

Annual Meeting of Stockholders

Management Change

Sales Agreement with Cowen ...

Earnings Reports

External Links:

Adverum Biotechnologies announced positive results from its LUNA Phase 2 trial and OPTIC extension trial for Ixo-vec, showing significant reductions in treatment burden for patients with wet AMD, with 88% to 92% reduction in anti-VEGF injections and

AI Assistant

ADVERUM BIOTECHNOLOGIES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.